Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B)
Breast Cancer Research and Treatment · 2026
DOI: 10.1007/s10549-026-08031-2 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Breast Cancer Research and Treatment, 2026. Verfasst von Meiko Nishimura und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Kotou-ku, Tokyo, 135-8550, …. Hauptthemen laut MEDLINE: Aminopyridines, Benzimidazoles, Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Kotou-ku, Tokyo, 135-8550, Japan. meiko.nishimura@jfcr.or.jp.
- Division of Early Clinical Development for Cancer, Department of Advanced Medical Development, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Kotou-ku, Tokyo, 135-8550, Japan. takahir…
- Department of Medical Oncology, NHO Nagoya Medical Center, Aichi, Japan.
- Department of Breast Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Kotou-ku, Tokyo, 135-8550, Japan.
- Department of Clinical Oncology, Toranomon Hospital, Tokyo, Japan.
- Department of Experimental therapeutics, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
ORCID-Profile: Meiko Nishimura
Zitieren
APA
Nishimura, M., Kogawa, T., Sugiyama, K., Ozaki, Y., Tanabe, Y., Funasaka, C., Kurozumi, S., Yoshimura, A., Iwasa, T., Sakai, H., Morita, M., Watanabe, S., Fujii, T., Yamamoto, M., Tsuji, Y., Terada, M., Ota, T., Tokunaga, S., Shimokawa, M., & Takano, T. (2026). Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B). Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-026-08031-2
Vancouver
Nishimura M, Kogawa T, Sugiyama K, Ozaki Y, Tanabe Y, Funasaka C, et al. Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B). Breast Cancer Research and Treatment. 2026. doi:10.1007/s10549-026-08031-2
BibTeX
@article{Nishimura2026,
author = {Nishimura, Meiko and Kogawa, Takahiro and Sugiyama, Keiji and Ozaki, Yukinori and Tanabe, Yuko and Funasaka, Chikako and Kurozumi, Sasagu and Yoshimura, Akiyo and Iwasa, Tsutomu and Sakai, Hitomi and Morita, Mitsunori and Watanabe, Satomi and Fujii, Takaaki and Yamamoto, Mitsugu and Tsuji, Yasushi and Terada, Mitsuo and Ota, Takayo and Tokunaga, Shinya and Shimokawa, Mototsugu and Takano, Toshimi},
title = {Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B)},
journal = {Breast Cancer Research and Treatment},
year = {2026},
doi = {10.1007/s10549-026-08031-2}
}
EUVIMED